Easy Access and Express Report Delivery Service
Targeted Oncology Drugs Market, Global Outlook and Forecast 2023-2029
Report ID
36456
Publisher
Market Monitor Global
Published Date
17-Oct
Delivery Format
PDF
No of Report Page
115
Editor's Rating
-
Report Details
This research report provides a comprehensive analysis of the Targeted Oncology Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Targeted Oncology Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Targeted Oncology Drugs, challenges faced by the industry, and potential opportunities for market players. The global Targeted Oncology Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Targeted Oncology Drugs market presents opportunities for various stakeholders, including Lung Cancer, Breast Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Targeted Oncology Drugs market. Additionally, the growing consumer demand present avenues for market expansion. The global Targeted Oncology Drugs market was valued at US$ 105830 million in 2022 and is projected to reach US$ 171400 million by 2029, at a CAGR of 7.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. Precision cancer medicine, also known as personalized or targeted cancer therapy, is driven by the growing understanding of cancer's molecular and genetic complexity. Advances in genomics and biomarker identification have enabled the development of therapies tailored to an individual's specific cancer characteristics. This approach offers the potential for more effective treatments with fewer side effects compared to traditional chemotherapy. The market benefits from increasing research in oncology, the rise of precision diagnostics, and the growing availability of targeted therapies. However, challenges include the high cost of genetic testing and targeted treatments, as well as the need for comprehensive molecular profiling. Additionally, regulatory approvals and insurance coverage for these therapies can be complex. To maximize the potential of precision cancer medicine, stakeholders must address these challenges, improve accessibility, and continue research into novel biomarkers and therapies to provide tailored cancer care for patients. Key Features: The research report on the Targeted Oncology Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders. Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Targeted Oncology Drugs market. Market Overview: The report provides a comprehensive overview of the Targeted Oncology Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Kinase Inhibitors, Monoclonal Antibodies), region, and application, highlighting the key drivers, challenges, and opportunities within each segment. Market Dynamics: The report analyses the market dynamics driving the growth and development of the Targeted Oncology Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Targeted Oncology Drugs market's trajectory. Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Targeted Oncology Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments. Market Segmentation and Forecast: The report segment the Targeted Oncology Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions. Technological Trends: The report should highlight the key technological trends shaping the Targeted Oncology Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences. Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Targeted Oncology Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders. Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Targeted Oncology Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments. Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Targeted Oncology Drugs market. Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts. Market Segmentation Targeted Oncology Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value. Market segment by Type
- Kinase Inhibitors
- Monoclonal Antibodies
- PARP Inhibitors
- Other
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Blood-related Cancer
- Other
- US
- Canada
- Mexico
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- Brazil
- Argentina
- Rest of South America
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
- AbbVie
- Johnson & Johnson
- Novartis
- Gilead Sciences
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Merck & Co
- Takeda
- Merck KGaA
- Seagen
- Eli Lilly
- Ono Pharmaceutical
- Pfizer
- GSK
- Exelixis
- Regeneron
- Innovent
- Hengrui Medicine
-
Table Of Content
1 Introduction to Research & Analysis Reports 1.1 Targeted Oncology Drugs Market Definition 1.2 Market Segments 1.2.1 Market by Type 1.2.2 Market by Application 1.3 Global Targeted Oncology Drugs Market Overview 1.4 Features & Benefits of This Report 1.5 Methodology & Sources of Information 1.5.1 Research Methodology 1.5.2 Research Process 1.5.3 Base Year 1.5.4 Report Assumptions & Caveats 2 Global Targeted Oncology Drugs Overall Market Size 2.1 Global Targeted Oncology Drugs Market Size: 2022 VS 2029 2.2 Global Targeted Oncology Drugs Market Size, Prospects & Forecasts: 2018-2029 2.3 Key Market Trends, Opportunity, Drivers and Restraints 2.3.1 Market Opportunities & Trends 2.3.2 Market Drivers 2.3.3 Market Restraints 3 Company Landscape 3.1 Top Targeted Oncology Drugs Players in Global Market 3.2 Top Global Targeted Oncology Drugs Companies Ranked by Revenue 3.3 Global Targeted Oncology Drugs Revenue by Companies 3.4 Top 3 and Top 5 Targeted Oncology Drugs Companies in Global Market, by Revenue in 2022 3.5 Global Companies Targeted Oncology Drugs Product Type 3.6 Tier 1, Tier 2 and Tier 3 Targeted Oncology Drugs Players in Global Market 3.6.1 List of Global Tier 1 Targeted Oncology Drugs Companies 3.6.2 List of Global Tier 2 and Tier 3 Targeted Oncology Drugs Companies 4 Market Sights by Product 4.1 Overview 4.1.1 By Type - Global Targeted Oncology Drugs Market Size Markets, 2022 & 2029 4.1.2 Kinase Inhibitors 4.1.3 Monoclonal Antibodies 4.1.4 PARP Inhibitors 4.1.5 Other 4.2 By Type - Global Targeted Oncology Drugs Revenue & Forecasts 4.2.1 By Type - Global Targeted Oncology Drugs Revenue, 2018-2023 4.2.2 By Type - Global Targeted Oncology Drugs Revenue, 2024-2029 4.2.3 By Type - Global Targeted Oncology Drugs Revenue Market Share, 2018-2029 5 Sights by Application 5.1 Overview 5.1.1 By Application - Global Targeted Oncology Drugs Market Size, 2022 & 2029 5.1.2 Lung Cancer 5.1.3 Breast Cancer 5.1.4 Prostate Cancer 5.1.5 Blood-related Cancer 5.1.6 Other 5.2 By Application - Global Targeted Oncology Drugs Revenue & Forecasts 5.2.1 By Application - Global Targeted Oncology Drugs Revenue, 2018-2023 5.2.2 By Application - Global Targeted Oncology Drugs Revenue, 2024-2029 5.2.3 By Application - Global Targeted Oncology Drugs Revenue Market Share, 2018-2029 6 Sights by Region 6.1 By Region - Global Targeted Oncology Drugs Market Size, 2022 & 2029 6.2 By Region - Global Targeted Oncology Drugs Revenue & Forecasts 6.2.1 By Region - Global Targeted Oncology Drugs Revenue, 2018-2023 6.2.2 By Region - Global Targeted Oncology Drugs Revenue, 2024-2029 6.2.3 By Region - Global Targeted Oncology Drugs Revenue Market Share, 2018-2029 6.3 North America 6.3.1 By Country - North America Targeted Oncology Drugs Revenue, 2018-2029 6.3.2 US Targeted Oncology Drugs Market Size, 2018-2029 6.3.3 Canada Targeted Oncology Drugs Market Size, 2018-2029 6.3.4 Mexico Targeted Oncology Drugs Market Size, 2018-2029 6.4 Europe 6.4.1 By Country - Europe Targeted Oncology Drugs Revenue, 2018-2029 6.4.2 Germany Targeted Oncology Drugs Market Size, 2018-2029 6.4.3 France Targeted Oncology Drugs Market Size, 2018-2029 6.4.4 U.K. Targeted Oncology Drugs Market Size, 2018-2029 6.4.5 Italy Targeted Oncology Drugs Market Size, 2018-2029 6.4.6 Russia Targeted Oncology Drugs Market Size, 2018-2029 6.4.7 Nordic Countries Targeted Oncology Drugs Market Size, 2018-2029 6.4.8 Benelux Targeted Oncology Drugs Market Size, 2018-2029 6.5 Asia 6.5.1 By Region - Asia Targeted Oncology Drugs Revenue, 2018-2029 6.5.2 China Targeted Oncology Drugs Market Size, 2018-2029 6.5.3 Japan Targeted Oncology Drugs Market Size, 2018-2029 6.5.4 South Korea Targeted Oncology Drugs Market Size, 2018-2029 6.5.5 Southeast Asia Targeted Oncology Drugs Market Size, 2018-2029 6.5.6 India Targeted Oncology Drugs Market Size, 2018-2029 6.6 South America 6.6.1 By Country - South America Targeted Oncology Drugs Revenue, 2018-2029 6.6.2 Brazil Targeted Oncology Drugs Market Size, 2018-2029 6.6.3 Argentina Targeted Oncology Drugs Market Size, 2018-2029 6.7 Middle East & Africa 6.7.1 By Country - Middle East & Africa Targeted Oncology Drugs Revenue, 2018-2029 6.7.2 Turkey Targeted Oncology Drugs Market Size, 2018-2029 6.7.3 Israel Targeted Oncology Drugs Market Size, 2018-2029 6.7.4 Saudi Arabia Targeted Oncology Drugs Market Size, 2018-2029 6.7.5 UAE Targeted Oncology Drugs Market Size, 2018-2029 7 Targeted Oncology Drugs Companies Profiles 7.1 AbbVie 7.1.1 AbbVie Company Summary 7.1.2 AbbVie Business Overview 7.1.3 AbbVie Targeted Oncology Drugs Major Product Offerings 7.1.4 AbbVie Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.1.5 AbbVie Key News & Latest Developments 7.2 Johnson & Johnson 7.2.1 Johnson & Johnson Company Summary 7.2.2 Johnson & Johnson Business Overview 7.2.3 Johnson & Johnson Targeted Oncology Drugs Major Product Offerings 7.2.4 Johnson & Johnson Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.2.5 Johnson & Johnson Key News & Latest Developments 7.3 Novartis 7.3.1 Novartis Company Summary 7.3.2 Novartis Business Overview 7.3.3 Novartis Targeted Oncology Drugs Major Product Offerings 7.3.4 Novartis Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.3.5 Novartis Key News & Latest Developments 7.4 Gilead Sciences 7.4.1 Gilead Sciences Company Summary 7.4.2 Gilead Sciences Business Overview 7.4.3 Gilead Sciences Targeted Oncology Drugs Major Product Offerings 7.4.4 Gilead Sciences Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.4.5 Gilead Sciences Key News & Latest Developments 7.5 Roche 7.5.1 Roche Company Summary 7.5.2 Roche Business Overview 7.5.3 Roche Targeted Oncology Drugs Major Product Offerings 7.5.4 Roche Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.5.5 Roche Key News & Latest Developments 7.6 Bristol-Myers Squibb 7.6.1 Bristol-Myers Squibb Company Summary 7.6.2 Bristol-Myers Squibb Business Overview 7.6.3 Bristol-Myers Squibb Targeted Oncology Drugs Major Product Offerings 7.6.4 Bristol-Myers Squibb Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.6.5 Bristol-Myers Squibb Key News & Latest Developments 7.7 Amgen 7.7.1 Amgen Company Summary 7.7.2 Amgen Business Overview 7.7.3 Amgen Targeted Oncology Drugs Major Product Offerings 7.7.4 Amgen Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.7.5 Amgen Key News & Latest Developments 7.8 AstraZeneca 7.8.1 AstraZeneca Company Summary 7.8.2 AstraZeneca Business Overview 7.8.3 AstraZeneca Targeted Oncology Drugs Major Product Offerings 7.8.4 AstraZeneca Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.8.5 AstraZeneca Key News & Latest Developments 7.9 Merck & Co 7.9.1 Merck & Co Company Summary 7.9.2 Merck & Co Business Overview 7.9.3 Merck & Co Targeted Oncology Drugs Major Product Offerings 7.9.4 Merck & Co Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.9.5 Merck & Co Key News & Latest Developments 7.10 Takeda 7.10.1 Takeda Company Summary 7.10.2 Takeda Business Overview 7.10.3 Takeda Targeted Oncology Drugs Major Product Offerings 7.10.4 Takeda Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.10.5 Takeda Key News & Latest Developments 7.11 Merck KGaA 7.11.1 Merck KGaA Company Summary 7.11.2 Merck KGaA Business Overview 7.11.3 Merck KGaA Targeted Oncology Drugs Major Product Offerings 7.11.4 Merck KGaA Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.11.5 Merck KGaA Key News & Latest Developments 7.12 Seagen 7.12.1 Seagen Company Summary 7.12.2 Seagen Business Overview 7.12.3 Seagen Targeted Oncology Drugs Major Product Offerings 7.12.4 Seagen Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.12.5 Seagen Key News & Latest Developments 7.13 Eli Lilly 7.13.1 Eli Lilly Company Summary 7.13.2 Eli Lilly Business Overview 7.13.3 Eli Lilly Targeted Oncology Drugs Major Product Offerings 7.13.4 Eli Lilly Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.13.5 Eli Lilly Key News & Latest Developments 7.14 Ono Pharmaceutical 7.14.1 Ono Pharmaceutical Company Summary 7.14.2 Ono Pharmaceutical Business Overview 7.14.3 Ono Pharmaceutical Targeted Oncology Drugs Major Product Offerings 7.14.4 Ono Pharmaceutical Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.14.5 Ono Pharmaceutical Key News & Latest Developments 7.15 Pfizer 7.15.1 Pfizer Company Summary 7.15.2 Pfizer Business Overview 7.15.3 Pfizer Targeted Oncology Drugs Major Product Offerings 7.15.4 Pfizer Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.15.5 Pfizer Key News & Latest Developments 7.16 GSK 7.16.1 GSK Company Summary 7.16.2 GSK Business Overview 7.16.3 GSK Targeted Oncology Drugs Major Product Offerings 7.16.4 GSK Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.16.5 GSK Key News & Latest Developments 7.17 Exelixis 7.17.1 Exelixis Company Summary 7.17.2 Exelixis Business Overview 7.17.3 Exelixis Targeted Oncology Drugs Major Product Offerings 7.17.4 Exelixis Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.17.5 Exelixis Key News & Latest Developments 7.18 Regeneron 7.18.1 Regeneron Company Summary 7.18.2 Regeneron Business Overview 7.18.3 Regeneron Targeted Oncology Drugs Major Product Offerings 7.18.4 Regeneron Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.18.5 Regeneron Key News & Latest Developments 7.19 Innovent 7.19.1 Innovent Company Summary 7.19.2 Innovent Business Overview 7.19.3 Innovent Targeted Oncology Drugs Major Product Offerings 7.19.4 Innovent Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.19.5 Innovent Key News & Latest Developments 7.20 Hengrui Medicine 7.20.1 Hengrui Medicine Company Summary 7.20.2 Hengrui Medicine Business Overview 7.20.3 Hengrui Medicine Targeted Oncology Drugs Major Product Offerings 7.20.4 Hengrui Medicine Targeted Oncology Drugs Revenue in Global Market (2018-2023) 7.20.5 Hengrui Medicine Key News & Latest Developments 8 Conclusion 9 Appendix 9.1 Note 9.2 Examples of Clients 9.3 Disclaimer
-
Inquiry Before Buying
WHY CHOOSE US
Discover Business Growth OpportunitiesMore than 10 Years Experience Employee SupportIn-depth and Comprehensive Analysis100+ Client Queries Handled Everyday -
Request Sample
WHY CHOOSE US
Easy Access and Express Report Delivery ServiceDiscover Business Growth OpportunitiesMore than 10 Years Experience Employee SupportIn-depth and Comprehensive Analysis100+ Client Queries Handled Everyday
